Low serum A-SYNUCLEIN and oligomer A-SYNUCLEIN levels in multiple sclerosis patients

Creative Commons License

Bilge N., Simsek F., Yevgi R., Ceylan M., Askın S.

JOURNAL OF NEUROIMMUNOLOGY, vol.350, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 350
  • Publication Date: 2021
  • Doi Number: 10.1016/j.jneuroim.2020.577432
  • Journal Name: JOURNAL OF NEUROIMMUNOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Psycinfo, Veterinary Science Database
  • Ataturk University Affiliated: Yes

Abstract

Introduction: Multiple sclerosis (MS) is an autoimmune, inflammatory, demyelinating neurodegenerative disease progressing with attacks. Alpha-synuclein (alpha-Syn), a neuronal protein, has been previously associated with the inflammation and development of neurodegenerative diseases. Although the cause of neurodegeneration in multiple sclerosis is mainly associated with inflammation, alpha-Syn may play a role in the pathogenesis of MS, as in other classical neurodegenerative diseases such as synucleinopathies. In multiple sclerosis, alpha-Syn has been directly studied in central nervous system lesions and cerebrospinal fluid (CSF). However, there are few studies approaching variations in peripheral alpha-Syn in MS. The aim of our study was to investigate the correlation between disease progression and other clinical parameters by measuring serum alpha-Syn and oligomer alpha-Syn levels in MS patients.